Provided by Tiger Trade Technology Pte. Ltd.

Liminatus Pharma LLC

0.2449
-0.0113-4.41%
Post-market: 0.28000.0351+14.33%19:55 EST
Volume:8.57M
Turnover:2.23M
Market Cap:7.61M
PE:-2.62
High:0.2814
Open:0.2718
Low:0.2401
Close:0.2562
52wk High:33.66
52wk Low:0.2250
Shares:31.06M
Float Shares:9.56M
Volume Ratio:0.79
T/O Rate:89.70%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.0935
EPS(LYR):-0.0316
ROE:--
ROA:-48.06%
PB:-4.62
PE(LYR):-7.75

Loading ...

Liminatus Pharma prices 13.8M shares at 29c in public offering

TIPRANKS
·
Feb 17

Liminatus Pharma Announces $4 Million Public Offering With Warrants

Reuters
·
Feb 17

Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering

THOMSON REUTERS
·
Feb 17

Liminatus Pharma Inc - Offering Price Set at $0.29 per Share

THOMSON REUTERS
·
Feb 17

Iris Acquisition Corp. II Files Initial Statement of Beneficial Ownership; Manish C. Shah Listed as Director

Reuters
·
Feb 12

Iris Acquisition Corp. II Announces Publication of Unqualified Independent Audit Report

Reuters
·
Feb 11

NASD Most Active Issues

Dow Jones
·
Feb 10

BRIEF-Liminatus Pharma Enters Settlement Agreement With Clear Street LLC

Reuters
·
Feb 10

Liminatus Pharma Inc - to Issue 4 Mln Shares of Common Stock to Holder in Exchange for Surrender and Cancellation of 805,377 Warrants

THOMSON REUTERS
·
Feb 10

Liminatus Pharma Inc - on Feb 6, Co Enters Settlement Agreement With Clear Street Llc - SEC Filing

THOMSON REUTERS
·
Feb 10

Liminatus Pharma Issues 4 Million Unregistered Shares to Settle Litigation

Reuters
·
Feb 10

NASD Most Active Issues

Dow Jones
·
Feb 06

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:08 PM

Reuters
·
Feb 05

Liminatus Pharma Faces Nasdaq Delisting Risk Over Sub-$1 Share Price

Reuters
·
Jan 27

Liminatus Pharma Faces Nasdaq Delisting Over Market Value Rule Breach

Reuters
·
Nov 26, 2025

Liminatus Pharma, Inc. (Nasdaq: Limn) Signs Mou With Capital Trust Group for USD 30 Million Equity Investment via an Earn-Out Mechanism and Future Strategic Cooperation

THOMSON REUTERS
·
Oct 30, 2025

Liminatus Pharma, Inc. (NASDAQ: LIMN) Signs MOU with Capital Trust Group for USD 30 Million Equity Investment via an earn-out mechanism and Future Strategic Cooperation

GlobeNewswire
·
Oct 30, 2025

Liminatus Pharma Receives Nasdaq Notice for Delayed Financial Report

Reuters
·
Aug 26, 2025